Addex soars on Phase IIa data for PD-LID therapy

Addex Therapeutics (SIX:ADXN) jumped CHF5.44 (84%) to CHF11.90 on Thursday after reporting late Wednesday that oral dipraglurant-IR plus levodopa met the primary safety endpoint in a Phase IIa trial t...